🚨 THIS IS WHY $MRNA.US IS EXPLODING! 📈

Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.

The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.

And the market reacted HARD:

$MRNA: +140% 🚀🔥

Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉

#MRNA #moderna #CancerCure #StocksTalks